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Abstract
Purpose—Inflammation may play an important role in the pathogenesis of diabetic macular
edema, a major cause of vision loss in persons with diabetes. The purpose of this study was to
evaluate combined antiinflammatory therapy and laser approaches for treating patients with
diabetic macular edema.
Methods—In this prospective, factorial, randomized, multicenter trial, we compared cyclo-
oxygenase-2 inhibitor (celecoxib) with placebo and diode grid laser with standard Early Treatment
Diabetic Retinopathy Study focal laser treatment in 86 participants with diabetic macular edema.
The primary outcome is change in visual acuity of ≥15 letters from baseline, and the secondary
outcomes include a 50% reduction in the retinal thickening of diabetic macular edema measured
by optical coherence tomography and a 50% reduction in leakage severity on fluorescein
angiography.
Results—Visual acuity and retinal thickening data from >2 years of follow-up did not show
evidence of differences between the medical and laser treatments. However, participants assigned
to the celecoxib group were more likely to have a reduction in fluorescein leakage when compared
with the placebo group (odds ratio = 3.6; P < 0.01).
Conclusion—This short-term study did not find large visual function benefits of treatment with
celecoxib or diode laser compared with those of standard laser treatment. A suggestive effect of
celecoxib in reducing fluorescein leakage was observed.
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Macular edema as a result of diabetic retinopathy can lead to central vision loss. It is one of
the major causes of visual loss in the United States,1 with ∼4.1 million Americans (age ≥40
years) estimated to have diabetic retinopathy.2 Vision-threatening diabetic retinopathy,
which includes both proliferative diabetic retinopathy and diabetic macular edema (DME),
is estimated to occur in ∼899,000 persons with the majority having type 2 diabetes.2 The
estimated proportions of persons with diabetes affected by macular edema are type 1
diabetes, 20%; type 2 diabetes, using insulin, 25%; and type 2 diabetes, not using insulin,
14%.3 The prevalence of diabetes is expected to substantially increase by 2020 with the
increasing prevalence of diabetes mellitus in the aging U.S. population.
When macular edema is established, focal laser photocoagulation reduces the risk of
moderate visual loss (loss of ≥15 letters from baseline on the Early Treatment Diabetic
Retinopathy Study [ETDRS] visual acuity charts) by 50%.4 However, treatment is often not
associated with improvement in visual acuity. Furthermore, the focal laser burns may result
in an increase in atrophy of the retinal pigment epithelium and progressive enlargement of
the initial focal scars of laser photocoagulation and eventually visual loss with central
scotomas and decreased color vision.5 Reduction of tissue destruction from laser burns while
maintaining the beneficial treatment effect would potentially reduce this long-term risk of
laser treatment.
These adverse side effects of the continuous wavelength laser used in the ETDRS technique
may theoretically be diminished by using a micropulse diode laser grid, which would result
in subthreshold burns with the accompanying reduction of damage from photocoagulation to
the retinal pigment epithelium.6,7 This technique has been evaluated in case series without
concurrent controls.8–10 This study was designed to compare the micropulse diode grid laser
with the standard ETDRS focal laser technique using the continuous wavelength laser.
Animal models of diabetic retinopathy demonstrate that inflammation plays an important
role in diabetic retinopathy.11 In early onset of diabetic retinopathy, up-regulation of cyclo-
oxygenase-2 (COX-2) occurs in retinal cells. This results in elevated prostaglandin
production, leading to an increased expression of vascular endothelial growth factor and an
increased risk of vascular leakage and retinal neovascularization.12 High doses of aspirin
and intermediate doses of COX-2 inhibitors (celecoxib) were apparently beneficial in early
experimental diabetic retinopathy.13 Other investigations have shown that periocular
celecoxib-poly (lactide-co-glycolide) microparticles inhibited elevations of retinal vascular
endothelial growth factor and other factors for as long as 60 days in a diabetic animal model.
14 Cyclo-oxygenase-2 inhibitors have been demonstrated to have antiangiogenic effects in a
rat model of ischemic proliferative retinopathy,15 and COX-2 expression is evident in
human retina of individuals with diabetes.8
These data suggest that treatment with a COX-2 inhibitor may be beneficial in the treatment
of DME. The purpose of this study was to gather pilot data to evaluate the feasibility of
mounting a larger multicenter study to evaluate the efficacy of celecoxib (a COX-2 inhibitor
and a nonsteroid anti-inflammatory drug) and of a modified laser photocoagulation
technique for the treatment of DME.
Study Design
This multicenter study was designed to investigate the feasibility and the proof-of-principle
study for 2 new treatment approaches for patients with diabetic retinopathy and clinically
significant macular edema (n = 100), potentially leading to initiation of a larger Phase 3
clinical trial.
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Design
A total of 86 participants were enrolled from December 2002 through November 2004 at 8
centers in the United States after reviewing and signing an informed consent form approved
by the respective sites' Institutional Review Boards. This study was prematurely terminated
because of safety concerns of celecoxib treatment reported by other large trials.16 Eligibility
criteria included age ≥18 years, evidence of type 1 or 2 diabetes, evidence of clinically
significant macular edema in at least one eye that requires laser treatment, and best-
corrected visual acuity of 20/400 or better using the ETDRS refraction and visual acuity
measurement protocol.17 In addition, exclusion criteria included the following: retinopathy
that may require scatter photocoagulation immediately, other retinal and systemic diseases
that might confound the outcomes (age-related macular degeneration, uveitis, drug toxicity,
sarcoidosis, inflammatory bowel disease, and so on), and a history of myocardial infarction
within the previous 2 years.
Participants were randomly assigned to receive an oral dose of 400 mg (200 mg 2 times a
day) of celecoxib or a matching placebo only daily for 3 months without laser, and the
medical therapy of celecoxib continued until the study was stopped. All participants and the
research team at each clinical site were masked to the study medication assignments.
Eligible eyes of participants were randomly assigned to receive either ETDRS focal laser18
or diode grid laser photocoagulation at their 3-month visit if macular edema persisted. If
both eyes were eligible, the right eye was designated as the study eye and was randomly
assigned to receive one of two laser therapies with the fellow eye assigned to receive the
alternate laser treatment. The first laser treatment was given when the study ophthalmologist
judged that the laser treatment was medically indicated, starting 3 months after
randomization to celecoxib or placebo. All laser treatments given during the first year were
performed according to the randomized laser treatment assignment. After 1 year of follow-
up, participants, who had their eyes initially treated with diode laser treatment, were allowed
to receive ETDRS laser treatment if additional treatment was required.
The micropulse diode technique was conducted with the 810 diode laser (Iris Medical
OcuLight SLx, IRIDEX Corporation, Mountain View, CA) by using the MicroPulse
operating mode. The treatment consisted of 125-μm size burns using a 10% duty cycle with
0.2-second pulse envelope duration with a maximum power of 1.8 W. These were
subthreshold burns that covered the entire area of macular edema with minimal clinical
detection or fluorescein angiographic changes associated with these laser burns. The ETDRS
focal treatment using yellow or green laser was a technique of direct laser photocoagulation
(50–100 μm spot size) at microaneurysms with light burns, not necessary to whiten or
darken the lesions. When no focal leakage was identified, a grid laser with light burns was
administered to sufficiently cover the area of edema. The burns were spaced greater than one
burn width apart with the sparing of the 500 μm from the center of the fovea.
Study visits were scheduled 3 and 6 months after enrollment and every 6 months thereafter
for a total of 3 years of follow-up. At each study visit, a comprehensive ophthalmic
examination was conducted including best-corrected visual acuity, slit-lamp biomicroscopy,
dilated fundus examination, retinal thickness with the optical coherence tomography (Stratus
OCT, Carl Zeiss Meditec, Dublin, CA), and fluorescein angiography (FA). Laser
photocoagulation therapy was considered for all participants with clinically significant
macular edema at each study visit. The study design and study data were reviewed and
monitored by the National Eye Institute's Data and Safety Monitoring Committee.
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Outcomes
The designated primary outcome was a ≥15-letter score improvement in best-corrected
visual acuity from baseline to the third year. The secondary outcome was a significant
reduction of macular edema at the end of the third year. A significant reduction was defined
as a 50% reduction in retinal thickening as measured by optical coherence tomography and a
50% reduction in leakage area as measured by FA. The optical coherence tomographies and
FAs were graded by the Fundus Photograph Reading Center at the University of Wisconsin,
whose graders were also masked to the assignment of the medical therapy.19,20 An
additional secondary outcome was the number of laser treatments required during the course
of the study. Safety measurements, including laboratory tests and adverse event assessments,
were also collected. Because of the premature study termination, outcomes through the
second year were analyzed. This early termination also reduced the power of the study
because the projected sample size of 100 was not achieved.
Change in Recruitment and Follow-Up
On December 17, 2004, the National Institutes of Health suspended the use of celecoxib for
all participants in a large colorectal cancer prevention clinical trial, the Adenoma Prevention
with Celecoxib Trial, because analyses by the trial's Data Safety and Monitoring Committee
found a two- to threefold increased risk of major fatal and nonfatal cardiovascular events for
participants taking celecoxib compared with those in the placebo group.21 In accordance
with the Data and Safety Monitoring Committee's action on other National Institutes of
Health-supported studies using a COX-2 inhibitor, the National Eye Institute Data and
Safety Monitoring Committee thoroughly reviewed all the reported adverse events as well as
the main study results on December 20, 2004, and recommended that the National Eye
Institute close the enrollment of participants and also suspend the use of celecoxib or
placebo for all enrolled participants. The participants were followed for 1 year after
discontinuing the study drug. This resulted in curtailed follow-up, especially for participants
who were enrolled late in the study, and lowered the power of the study evaluating the long-
term effects of study treatments.
Statistical Methods
The cross-sectional analyses of the primary and secondary outcomes for each study visit
were examined using two-sample mean and proportion comparison tests. The generalized
estimating equation method was used to adjust the difference between the two groups for the
correlation between bilateral outcomes.22 When a statistically significant difference existed
between the two groups, the extended generalized estimating equation method was applied
to investigate the trends and variations in the outcome measures during the course of the
study.23 To allow for the unequal length of follow-up of each participant, the proportional
hazard model for the first occurrence of event of interest was also considered if the result
from the generalized estimating equation model was statistically significant. Parsimonious
and well-fitted models for each outcome were derived by backward variable selection of the
following variables: age and baseline level of each outcome. All the data analyses were
conducted using SAS version 8.2 (SAS Institute, Inc., Cary, NC).
Results
Baseline Demographics and Characteristics
Eighty-six participants with diabetic retinopathy and clinically significant macular edema
were enrolled (Table 1). Forty-seven participants were randomly assigned to the placebo
group (34% women and 74% white) and 39 participants to the celecoxib group (43% women
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and 59% white) (Figure 1). The median ages for the placebo and celecoxib participants were
61 and 58 years, respectively. All the participants have received diabetic treatments,
including insulin, oral medication, or diet (94% and 92% of placebo and celecoxib
participants, respectively, on insulin or oral medication for at least 1 year). Participants with
both eyes eligible for the study numbered 14 in the placebo group and 9 in the celecoxib
group. The median visual acuity score and retinal thickening (thickness −175 μm) at the
center subfield at baseline was 75 letters (20 of 32) and 135 μm and 82 letters (20 of 25) and
85 μm for the placebo and celecoxib groups, respectively. There was an imbalance of the
retinal thickness between the placebo and celecoxib groups.
Follow-Up and Duration of Drug Treatment
Among the 86 enrolled participants, 78 (91%) participants (43 in the placebo group and 31
in the celecoxib group) completed 1 year of follow-up and 54 (63%) participants (29 in the
placebo group and 25 in the celecoxib group) finished the 2-year follow-up visit (Table 2).
Before cessation of the study therapy on December 31, 2004, 47 participants (26 in the
placebo group and 21 in the celecoxib group) had received study medication for at least 1
year. Until study closeout, 9 placebo participants (19%) and 3 celecoxib participants (8%)
experienced a serious, cardiovascular adverse event (exact P = 0.225). The data from this
trial collected through January 31, 2005, have been analyzed with the data from 5 other
randomized, controlled trials of celecoxib supported by the National Cancer Institute in a
project called the Cross-Trials Safety Analysis for the risk of serious cardiovascular events
caused by the use of celecoxib.15 This small study has too few participants to yield clinically
meaningful data (Table 2).
Visual Acuity
Table 3 (Figure 2) compares mean changes in visual acuity by treatment group (placebo or
celecoxib) at each study visit. No significant differences were detected in mean visual
acuity. Additionally, the rates of vision loss of ≥3 lines from baseline to 1 and 2 years were
also similar (P = 0.82 and P = 0.66 for comparison of mean changes, respectively). During
the first year, 7 placebo participants (12%) and 3 celecoxib participants (8%) lost ≥3 lines of
vision. Three placebo participants (5%) and 2 celecoxib participants (5%) gained ≥3 lines of
vision. Overall, the drug-treated group and placebo group do not differ significantly in visual
acuity results (either improvement or worsening) at any of the time points.
Laser Treatments
Fifty-eight participants needed at least one laser treatment for their macular edema (nine
participants needed laser treatment in both eyes and received different laser treatments in
each). More specifically, 41 eyes of 34 participants in the placebo group (34 of 47 [72%])
and 26 eyes of 24 participants in the celecoxib group (24 of 39 [62%]) required at least 1
laser treatment throughout the follow-up period. The participants in the placebo group had
slightly higher rates of requiring laser treatments than those participants in the celecoxib
group, but this was not statistically significant (odds ratio [OR] = 1.63; P = 0.36 for
participants and OR = 1.73; P = 0.15 for eyes). After the 1-year follow-up visit, the
investigator was permitted to treat the participants with either lasers (11 participants
switched from diode laser to ETDRS laser). Table 4 compares the proportion of laser
retreatment among the laser-treated eyes. The proportion was estimated from a binomial
probability distribution with the denominator being the number of opportunities to receive
laser retreatment before the last visit. These analyses do not provide evidence that celecoxib
reduces the need for laser retreatment (P ≥ 0.54).
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Fluorescein Angiographic Leakage Severity
The number of participants eligible for the analysis of fluorescein leakage was decreased
because the FAs of 4 participants were not gradable, and 6 participants had stage 1 or less in
severity of macular edema at baseline, making them ineligible for analysis of the reduction
of FA leakage by 2 steps. At the first-year follow-up visit, participants in the celecoxib
group had a higher chance of having reduced FA leakage severity than did the participants in
the placebo group (43% vs 26% complete case analysis; 33% vs 22% intention-to-treat
analysis), but this difference was not statistically significant (exact P > 0.19). At the second-
year follow-up visit, 3 of 24 (12%) participants in the placebo group and 9 of 20 (45%)
participants in the celecoxib group experienced a ≥2-step reduction in leakage severity
(exact P = 0.02). These statistically significant effects of celecoxib on the 2-step leakage
severity reduction also appear in the intention-to-treat analysis that treats all missing
outcomes as failures. Although the statistical significance levels are diminished, the effects
are still suggestive in the most conservative analysis (OR = 4.11; exact P = 0.057 at year 2).
Table 5 presents repeated measures analyses of a ≥2-step reduction in leakage severity.
Celecoxib participants had reduced leakage severity with a higher likelihood than did
placebo participants (unadjusted OR = 2.45; P = 0.054 and unadjusted OR = 3.31; P = 0.002
for 1- and 2-year results, respectively). Adjusting for baseline leakage severity, follow-up
year, and laser treatment, the reduction in leakage associated with celecoxib remains
significant at 2 years (OR = 3.52; P = 0.002). Repeated measure analyses based on the entire
follow-up data set have similar results. Figure 3 displays Kaplan–Meier estimates of the
incidence of the first event of a ≥2-step reduction in leakage severity. Cox proportional
hazards model, for the time to the first occurrence of a ≥2-step reduction in leakage severity,
shows that there is a 1.8 times higher chance of reduction in leakage severity (P = 0.067) in
participants assigned to the celecoxib group than that in participants assigned to the placebo
group. Figure 4 shows the typical increased fluorescein leakage in the study eye of a
participant at baseline (Figure 4A). There was a reduction in the fluorescein leakage of 2
steps along the severity scale at 24 months (Figure 4B).
Retinal Thickening Measured on Optical Coherence Tomography
Retinal thickening measurements at the center subfield, the excessive thickness compared
with that of a normal eye (defined as 175 μm), are right skewed and subject to high variation
and therefore transformation may be required (e.g., log transformation); however, the results
based on this transformation (not shown) do not differ from those based on raw scales.
Participants in both treatment groups presented with reduced retinal thickening by ∼26 μm
to 31 μm on average during the first year (P = 0.66 in Table 6) and by >64 μm during the
second year (P = 0.94 in Table 6). In the first year, 4 of 40 eyes in the placebo group (10%)
and 5 of 27 eyes in the celecoxib group (18%) had a ≥50% reduction in retinal thickening.
Eleven eyes (27%) of the placebo participants and 8 eyes (30%) of the celecoxib participants
had at least a 25% reduction in the first year. These reduction rates do not differ between the
two treatment groups (P ≥ 0.26 for either size reduction). Within the specific laser type, both
treatment groups showed a similar degree of reduction (∼30 μm) in retinal thickening.
Overall, there are no statistically significant differences in changes in retinal thickening by
treatment group or laser treatment.
Discussion
The results of this pilot study suggest that it is feasible to mount a multicenter study to
evaluate the role of medical and laser therapies for the treatment of DME. However, the
COX-2 inhibitor chosen for this study, celecoxib, was associated with an increased risk of
cardiovascular disease in other clinical trials. The increased risk observed in several large
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trials makes it difficult to launch a large clinical trial in persons with diabetes who are
already at an increased risk for cardiovascular disease.
This pilot study has insufficient power to evaluate the potential beneficial effect of both the
medical and laser treatment approaches. Although the early discontinuation of celecoxib in
this study may have reduced any measurable beneficial effects, these data did not provide
evidence of the treatment effects from these therapeutic strategies. The inflammatory
pathways found in the animal data are compelling, and it is intriguing that the medical
therapy with the COX-2 inhibitor resulted in an apparently greater reduction in fluorescein
leakage compared with the placebo group. These leakage results were verified by regrading
the leakage at the centralized reading center with similar results. This apparent reduction in
fluorescein leakage suggests that COX-2 inhibitors or other anti-inflammatory treatments
may have a role in therapy for DME.
Focal laser photocoagulation treatment given in the focal ETDRS fashion is the only therapy
currently demonstrated to be beneficial for the treatment of DME. The ETDRS showed that
this treatment reduced the 3-year rate of moderate vision loss (≥3 lines of acuity loss) by
50%.6 However, only 17% of the treated eyes that had baseline acuity worse than 20/40
experienced moderate visual gain (≥3 lines of acuity improvement).6 Our results from the
laser arm showed that there were no large differences detected between the two laser
techniques evaluated in this study. It should also be noted that during the first year, 11 of
those assigned to diode laser were switched to the ETDRS type of treatment.
This pilot study was too small and its follow-up too short to evaluate whether some of the
possible side effects of laser photocoagulation such as enlargement of laser burns, increases
in scotomas, and decreased vision can be attenuated with diode laser treatment. Studies with
longer duration and larger numbers of participants would be required to answer this
question.
The current investigations of possible therapies for DME have included intravitreal
triamcinolone,24 oral protein kinase C inhibitors,25 intravitreal aptamers,26,27 antibodies
directed against vascular endothelial growth factor,28,29 and vitrectomy.30 Intravitreal
triamcinolone injection does address the issue of inflammation, but intravitreal injections are
accompanied by the potential adverse effects of raised intraocular pressure, the development
of cataract, and the rare possibility of endophthalmitis. A recently completed trial of
intravitreal triamcinolone injections versus DME confirmed the importance of laser
photocoagulation after 2 years of follow-up.31 Intravitreal steroids may have some short-
term beneficial effect, and the effects of combined steroids and laser are yet to be fully
evaluated. Studies are also underway to evaluate the use of intravitreal antivascular
endothelial growth factor therapy for DME.
Laboratory data and observational studies suggest that inflammation may play a potential
role in the pathogenesis of diabetic macular retinopathy. Although this study failed to
provide evidence that COX-2 inhibitors may be effective in the treatment of DME, there was
some evidence of a reduction of fluorescein leakage, and future investigations of anti-
inflammatory agents for the treatment of DME seem warranted.
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Fig. 1.
The enrollment and randomization of the study participants.
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Fig. 2.
The mean change in visual acuity in participants assigned to celecoxib or placebo.
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Fig. 3.
Life table estimates of the time to progression in fluorescein leakage in participants assigned
to celecoxib or placebo.
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Fig. 4.
At baseline (A), the clinically significant macular edema of this left study eye of a 31-year-
old man with a 16-year history of diabetes had fluorescein leakage that was reduced
significantly at 24 months. He did not receive laser photocoagulation during the course of
the study (B).
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Table 1
Participant Demographic and Baseline Characteristics by Treatment Group
Placebo Celecoxib
Randomized participants 47 (100%) 39 (100%)
Sex, female 16 (34%) 17 (43%)
Race, white 35 (74%) 23 (59%)
Age (median years) 61 58
≥1-year diabetic treatment of insulin or oral medication 44 (94%) 36 (92%)
Number of eyes* 61 48
VA (median letter score) 75 82
Retinal thickening at the center subfield (median)† 135 85
Laser type assigned for eligible eyes
 Diode 31 25
 ETDRS 30 23
Laser type given for eligible eyes by randomization
 Diode 18 13
 ETDRS 23 13
*
Both eyes are eligible in 23 participants (14 in the placebo group and 9 in the celecoxib group).
†
Retinal thickening at the center subfield is excessive thickness >175 (the difference of retinal thickness between the study participants and a
normal subject).
VA, visual acuity.
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Table 2
Participants' Follow-Up and Duration on Study Therapy Before Mandated
Discontinuation by Treatment Group
Placebo Celecoxib P
Randomized participants 47 (100%) 39 (100%)
Follow-up (months)*
 <12 2 (4%) 6 (15%)
 ≥12–<24 16 (34%) 8 (21%)
 ≥24 29 (62%) 25 (64%)
Duration (months) on drug treatment†
 <12 21 (45%) 18 (46%)
 ≥12–<24 24 (51%) 19 (49%)
 ≥24 2 (4%) 2 (5%)
Serious cardiovascular events
Entire follow-up‡ 9 (19%) 3 (8%) 0.225
CTSA§ 6 (13%) 2 (5%) 0.283
*
Follow-up is based on the most recent clinical/ophthalmic examination visit.
†
Follow-up before mandatory discontinuation of masked and randomized study medication (either placebo or celecoxib).
‡
Follow-up until study closeout.
§
Cross-Trials Safety Analysis (CTSA, this includes this study of diabetic retinopathy and other studies of randomized, controlled trials of celecoxib
for adenoma of the gastrointestinal system, breast cancer, and for Alzheimer disease) has adjudicated cardiovascular adverse events from
randomization to 1 year after study therapy discontinuation (January 31, 2005); 1 death because of stroke of a placebo participant is not included.
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Table 4
Laser Retreatments Among Laser-Treated Eyes
Number of Eyes With Laser Retreatment Placebo (%)* Celecoxib (%)* OR† P
Diode (19 placebo; 10 celecoxib) 43 42 0.96 0.90
ETDRS (22 placebo; 16 celecoxib) 55 56 1.20 0.54
Total (41 placebo; 26 celecoxib) 49 51 1.11 0.65
*
Rates were estimated using a binomial probability model with the number of opportunities to receive laser retreatments before last visit.
†
Reference group is placebo.
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Table 5
The Reduction of Fluorescein Leakage by 2 or More Steps in Eyes With at Least Stage 2
Severity of Macular Edema at Baseline in Those Subjects Assigned to Celecoxib
Treatment*
Month Covariate Adjustment Factors OR† 95% CI for OR P
12 None 2.45 0.99−6.09 0.054
Baseline severity and year 2.43 0.98−6.07 0.056
Baseline severity, year, and laser treated 2.47 0.99−6.15 0.052
24 None 3.31 1.54−7.12 0.002
Baseline severity and year 3.50 1.59−7.67 0.002
Baseline severity, year, and laser treated 3.52 1.61−7.71 0.002
36 None 3.60 1.71−7.59 0.001
Baseline severity and year 3.74 1.73−8.10 0.001
Baseline severity, year, and laser treated 3.75 1.73−8.11 0.001
*
Analysis of variance model for repeated measures.
†
Reference group is placebo.
CI, confidence interval.
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